- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
Business description – A detailed description of the company’s operations and business divisions.
Corporate strategy – GlobalData’s summarization of the company’s business strategy.
SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history – Progression of key events associated with the company.
Major products and services – A list of major products, services and brands of the company.
Key competitors – A list of key competitors to the company.
Key employees – A list of the key executives of the company.
Executive biographies – A brief summary of the executives’ employment history.
Key operational heads – A list of personnel heading key departments/functions.
Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights
Octapharma AG (Octapharma) is a human protein product manufacturer. The company focuses on developing and producing medicines through human proteins from human plasma and cell lines. It treats patients worldwide with products across immunotherapy, hematology, and critical care therapeutic areas. The company sources plasma from company-owned plasma donation centers and other external sources. Octapharma owns plasma donation centers in the US and Germany and owns production facilities in Austria, Germany, France, Mexico, and Sweden. Its production plants carry out plasma fractionation and purification, pharmaceutical production, research and development, product labeling, packaging, storage, and distribution. Octapharma is headquartered in Lachen, Switzerland.
Octapharma AG Key Recent Developments
Jun 06,2023: Octapharma Presents New Data at ISTH 2023 in an Ongoing Commitment to Improve the Lives of People With Bleeding Disorders Feb 02,2023: European authorities approve lyophilized S/D treated plasma OctaplasLG for pre-hospital transfusion
Reasons to Buy
Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note:Some sections may be missing if data is unavailable for the company.
Section 1 - About the Company
Octapharma AG - Key Facts
Octapharma AG - Key Employees
Octapharma AG - Major Products and Services
Octapharma AG - History
Octapharma AG - Company Statement
Octapharma AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Octapharma AG - Business Description
R&D Overview
Octapharma AG - Corporate Strategy
Octapharma AG - SWOT Analysis
SWOT Analysis - Overview
Octapharma AG - Strengths
Octapharma AG - Weaknesses
Octapharma AG - Opportunities
Octapharma AG - Threats
Octapharma AG - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Octapharma AG, Recent Deals Summary
Section 4 – Company’s Recent Developments
Jun 06, 2023: Octapharma Presents New Data at ISTH 2023 in an Ongoing Commitment to Improve the Lives of People With Bleeding Disorders
Feb 02, 2023: European authorities approve lyophilized S/D treated plasma OctaplasLG for pre-hospital transfusion
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Octapharma AG, Key Facts
Octapharma AG, Key Employees
Octapharma AG, Major Products and Services
Octapharma AG, History
Octapharma AG, Other Locations
Octapharma AG, Subsidiaries
Octapharma AG, Key Competitors
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Octapharma AG, Recent Deals Summary
List of Figures
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Octapharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024